摘要：在《中药新药临床研究技术指导原则》的编制过程中,常面临着中医症状学的评价问题。功能性胃肠病(Functional gastrointestinal disorders,FGIDs)是消化系统常见的一组疾病,其在临床诊断及治疗方面均以症状学为主,与中医学以症状为靶点进行诊断治疗有一定的类同性。因而此次以FGIDs为代表,组织专家对其临床疗效评价中症状学问题进行讨论,涉及内容包括指导原则的总体思路及设计、症状学研究在FGIDs乃至功能性疾病研究中的意义、FGIDs中的症状学评价中遇到的问题及解决方案等,并达成一系列重要共识,希望借此推进FGIDs指导原则编制过程中相关问题的解决,并为今后其他疾病中涉及症状学问题的处理提供参考。

摘要：在对症状学诊断常见误区总结反思的基础上,以医学层面的辩证思维为论证依据,演绎推理为主要形式,建立论证链,结合昏迷和头痛的具体案例,探讨症状学论证辩误教学法的设计应用,从医学知识讲授和哲学思维两方面进行导学和训练,在提高教学质量的同时,培养批判性思辨能力和正确思维方法。

摘要：临床常见症状的评估是课程的重要组成部分之一,同时也是教学中的难点.

摘要：Objective: The objective of the study was to evaluate the relationship among polyp site, number, diameter, and symptomatology in endometrial polyps in reproductive and postmenopausal women. Study design: One hundred fifty-five subjects with endometrial polyps were evaluated retrospectively. Sociodemographic characteristics, endometrial thickness, polyp number, diameter, and site were reviewed, and their relations with abnormal uterine bleeding were tested. Results: A total of 36.1% of the patients in the postmenopausal group and 44.4% of the patients in the reproductive-aged group were asymptomatic. In addition, 37.3% of polyps in the reproductive-aged and 29.2% in the postmenopausal group were multiple. Polyp number, diameter, and site were not different among the 2 groups (P = .282, P = .469, and P = .485, respectively). When patients were evaluated as a whole, symptomatology was not related with polyp number, diameter, and site (P = .677, P = .334, and P = .699, respectively). Conclusion: Many endometrial polyps are asymptomatic and multiple in nature. Polyp site, number, and diameter do not correlate with symptomatology.

摘要：中药上市后证候疗效再评价是对上市前证候疗效评价的必要补充,由于研究阶段及研究目标的转变,注定其需要在评价方法上有所突破和创新,而考虑中医药证候理论的学术特色,围绕证候疗效评价设计与实施过程的关键环节,分析证候疗效评价中普遍存在的共性问题,是改变当前证候疗效评价研究现状的迫切需求。通过分析中医药疗效评价的类型及层次,阐释中药上市后证候疗效再评价的现状及需求,进而提出重视中药上市后证候疗效再评价症状学研究,包括症状单元研究、规范症状表述、症状筛选及优化等,借鉴有效性登记式研究设计,结合探讨因果关系研究理念等,以期对建立中药上市后证候疗效再评价方法学有所启迪。

摘要：目的探讨补肾活血法对慢性肾功能衰竭肾性骨病(RBD)患者甲状旁腺功能亢进及骨代谢异常的改善作用及其机理,并与单纯补肾法相对比。方法采用交叉设计方法比较补肾活血法与单纯补肾法对肾性骨病患者全段甲状旁腺激素(I-PTH)、骨特异性碱性磷酸酶(BAP)指标的影响。结果补肾活血法治疗后血清I-PTH、BAP水平较治疗前均有所下降;单纯补肾法治疗后血清I-PTH、BAP水平较治疗前均显著升高。结论补肾活血中药可以缓解RBD患者甲状旁腺功能亢进的状态,有效改善骨代谢异常,从而延缓RBD的进展。